Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow ...

Pfizer has a diversified portfolio, including successful vaccines and promising new drugs. Read more to see why I upgrade PFE ...

Health care companies are taking a step back to better understand patients' experiences after a powerful U.S. health ...

Pfizer has had its own issues with falling Covid-19 vaccine sales weighing on its stock performance over the recent years.

On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.57 which represents a decrease of $-0.53 or -2.03% from the prior close of $26.1. The stock opened at $26.1 and touched a low of ...

We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Guggenheim lowered the firm’s price target on Pfizer (PFE) to $33 from $35 and keeps a Buy rating on the shares. Pfizer will be releasing their ...

Today, Benzinga 's options scanner spotted 29 uncommon options trades for Pfizer. This isn't normal. The overall sentiment of these big-money traders is split between 31% bullish and 62%, bearish. Out ...

Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $25.73 which represents a slight increase of $0.03 or 0.12% from the prior close of $25.7. The stock opened at $25.74 and touched a low of ...

Currently, Pfizer has a Zacks Rank of #2 (Buy), while Novo Nordisk has a Zacks Rank of #3 (Hold). This means that PFE's earnings estimate revision activity has been more impressive, so investors ...